Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $73 Price Target

Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $73 price target.

BenzingaJun 27 21:38

A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $24 to $73

On Jun 27, major Wall Street analysts update their ratings for $Intellia Therapeutics(NTLA.US)$, with price targets ranging from $24 to $73.BMO Capital analyst Kostas Biliouris maintains with a buy ra

Futu NewsJun 27 21:00 · Ratings

Cathie Wood's Ark Invest Acquires $7.3M Worth Of Shares In This Promising Netflix Competitor, Sells Off Coinbase Stock Amid Bitcoin Slump

On Wednesday, Cathie Wood-led Ark Invest made significant trades in Roku Inc (NASDAQ:ROKU) and Coinbase Global Inc (NASDAQ:COIN), amidst a volatile market. These prominent trades were part of a series

BenzingaJun 27 11:33

A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $29 to $95

On Jun 26, major Wall Street analysts update their ratings for $Intellia Therapeutics(NTLA.US)$, with price targets ranging from $29 to $95.Citi analyst David Lebovitz maintains with a hold rating, an

Futu NewsJun 26 21:00 · Ratings

Intellia Therapeutics: Dulac Recently Served as CFO of Fate Therapeutics >NTLA

Intellia Therapeutics: Dulac Recently Served as CFO of Fate Therapeutics >NTLA

Dow JonesJun 26 19:33

Express News | Intellia Therapeutics Inc - Glenn Goddard to Step Down as CFO Effective June 30, 2024

BreakingsJun 26 19:30